Novartis agrees to buy Chinook Therapeutics for up to $3.5 billion

The deal will hand Novartis exposure to Chinook's pipeline for kidney disease treatments.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.